New Alzheimer's drug shows promise in early safety trial
NCT ID NCT05804383
First seen Nov 06, 2025 · Last updated May 15, 2026 · Updated 20 times
Summary
This early-stage study tested the safety of a new drug called BMS-984923 in 51 healthy older adults and people with Alzheimer's disease. The goal was to see if the drug is safe and tolerable, and to understand how it works in the body. This is a first step toward possibly easing Alzheimer's symptoms in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Spaulding Clinical Research
West Bend, Wisconsin, 53095, United States
-
Yale University
New Haven, Connecticut, 06511, United States
Conditions
Explore the condition pages connected to this study.